WEDNESDAY, 17th OCTOBER 2018 COMMENCING 09:30 AM
AT THE COPTHORNE HOTEL CARDIFF, COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting 1/AWMSG/1018

5. Chairman's report (verbal update)

6. Appraisal 1: Full Submission
   Semaglutide (Ozempic®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in addition to other medicinal products for the treatment of diabetes 2/AWMSG/1018

To protect commercial confidentiality the following appraisals will be held in private

7. Appraisal 2: Full Submission (WPAS)
   Conestat alfa (Ruconest®) for the treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency 3/AWMSG/1018

8. Appraisal 3: Limited Submission (PAS)
   Ipilimumab (Yervoy®) as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age to <18 years of age 4/AWMSG/1018

The meeting will now open to the public for the committee decisions

Date of next meeting – Wednesday, 14th November 2018 in Cardiff